Stay updated with breaking news from Foresight Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
By Colin Kellaher Shares of Allogene Therapeutics tumbled more than 15% on Friday after the clinical-stage biotechnology company unveiled a...
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal trial (ALPHA3) evaluating cema-cel as a consolidation therapy in large B-cell lymphoma (LBCL) patients
Shares of Applied Therapeutics, Inc.
Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 -- Allogene...